Rockefeller Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Rockefeller Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-56	Closed	-$19K	–	2234
2022 Q4	$19K	Hold	56	–	–	﹤0.01%	2818
2022 Q3	$10K	Hold	56	–	–	﹤0.01%	3072
2022 Q2	$11K	Sell	56 -69	-55%	-$14.5K	﹤0.01%	3053
2022 Q1	$41K	Hold	125	–	–	﹤0.01%	2384
2021 Q4	$40K	Hold	125	–	–	﹤0.01%	2315
2021 Q3	$60K	Buy	125 +69	+123%	+$30.3K	﹤0.01%	2054
2021 Q2	$26K	Hold	56	–	–	﹤0.01%	2366
2021 Q1	$38K	Hold	56	–	–	﹤0.01%	2003
2020 Q4	$41K	Hold	56	–	–	﹤0.01%	1739
2020 Q3	$39K	Sell	56 -7	-11%	-$5.26K	﹤0.01%	1578
2020 Q2	$53K	Buy	+63	New	+$41.1K	﹤0.01%	1394

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Rockefeller Capital Management's BTAI Position: Q1 2023 in Review

Rockefeller Capital Management sold out of BioXcel Therapeutics (BTAI) in Q1 2023, closing a stake of 56 shares — an estimated $19K sold.

Rockefeller Capital Management first reported a position in BTAI in Q2 2020 and held it in 11 quarters. The position peaked at $60K in Q3 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2023.

Rockefeller Capital Management reported no remaining BioXcel Therapeutics position as of Q1 2023 after selling out during the quarter.
Rockefeller Capital Management sold 56 BioXcel Therapeutics shares in Q1 2023, an estimated $19K.
Rockefeller Capital Management first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 11 quarters.
Rockefeller Capital Management's BioXcel Therapeutics position peaked at $60K in Q3 2021.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.